» Articles » PMID: 31504810

Diffuse Midline Glioma with H3 K27M Mutation: a Comparison Integrating the Clinical, Radiological, and Molecular Features Between Adult and Pediatric Patients

Overview
Journal Neuro Oncol
Specialties Neurology
Oncology
Date 2019 Sep 11
PMID 31504810
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Diffuse midline glioma (DMG), H3 K27M mutant, occurs in both adult and pediatric populations. The characteristics of the 2 DMG groups were systematically explored in this study.

Methods: H3 K27M-mutant DMG was diagnosed in 116 patients at Beijing Tiantan Hospital from May 2016 to December 2018 who were included in our study. Patients were classified into an adult group (n = 57; 49.1%) and a pediatric group (n = 59; 50.9%). Clinical, radiological, and molecular features were compared between the groups. Univariate and multivariate analyses were performed to identify prognostic factors.

Results: Compared with the adult group, pediatric patients had a younger age (8.9 ± 4.1 y vs 35.1 ± 11.8 y, P < 0.001), a lower preoperative Karnofsky performance scale score (62.9 ± 15.5 vs 72.1 ± 16.5, P = 0.004), a lower rate of total resection (5.7% vs 26.8%, P = 0.009), a larger tumor size (4.4 ± 0.9 vs 3.9 ± 1.5 cm, P = 0.045), a higher Ki-67 index (63.0% vs 37.8%, P = 0.047), and higher rates of postoperative cranial nerve palsy (61.0% vs 36.8%, P = 0.009) and ataxia (45.8% vs 26.3%, P = 0.029). Adult DMG was located predominantly in the thalamus, while the predilection site for pediatric DMG was brainstem (P < 0.001). Kaplan-Meier plot showed that the median survival of adult and pediatric DMG was 16.0 (9.7-22.3) months and 10.0 (8.3-11.7) months, respectively, which imparted a significant difference (P = 0.008). Age at diagnosis, radiotherapy, and motor deficit were confirmed as independent prognostic factors according to the multivariate analysis (P < 0.05).

Conclusion: Compared with adult patients, children with H3 K27M-mutant DMG confer distinct clinical, radiological, and molecular characteristics and have a dismal prognosis. Radiotherapy is an independent factor associated with prolonged survival.

Citing Articles

Pediatric H3K27M‑mutant diffuse midline glioma with vertebral metastasis: A case report and literature review.

Ge X, Yang Y, Wang W, Tian L, Zhang G, Tian Z Oncol Lett. 2024; 27(2):48.

PMID: 38192660 PMC: 10773191. DOI: 10.3892/ol.2023.14181.


Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis.

Nduom E, Glod J, Brown D, Fagan M, Dalmage M, Heiss J PLoS One. 2023; 18(9):e0291068.

PMID: 37682953 PMC: 10490936. DOI: 10.1371/journal.pone.0291068.


Deep learning-based prediction of H3K27M alteration in diffuse midline gliomas based on whole-brain MRI.

Huang B, Zhang Y, Mao Q, Ju Y, Liu Y, Su Z Cancer Med. 2023; 12(16):17139-17148.

PMID: 37461358 PMC: 10501256. DOI: 10.1002/cam4.6363.


A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma.

Peng Y, Ren Y, Huang B, Tang J, Jv Y, Mao Q Sci Rep. 2023; 13(1):9970.

PMID: 37340065 PMC: 10282027. DOI: 10.1038/s41598-023-37078-0.


Histological and molecular classifications of pediatric glioma with time-dependent diffusion MRI-based microstructural mapping.

Zhang H, Liu K, Ba R, Zhang Z, Zhang Y, Chen Y Neuro Oncol. 2023; 25(6):1146-1156.

PMID: 36617263 PMC: 10237431. DOI: 10.1093/neuonc/noad003.


References
1.
Lu V, Alvi M, McDonald K, Daniels D . Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis. J Neurosurg Pediatr. 2018; 23(3):308-316. DOI: 10.3171/2018.9.PEDS18419. View

2.
Li Y, Qian Z, Xu K, Wang K, Fan X, Li S . Radiomic features predict Ki-67 expression level and survival in lower grade gliomas. J Neurooncol. 2017; 135(2):317-324. DOI: 10.1007/s11060-017-2576-8. View

3.
Schreck K, Ranjan S, Skorupan N, Bettegowda C, Eberhart C, Ames H . Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol. 2019; 143(1):87-93. PMC: 6482123. DOI: 10.1007/s11060-019-03134-x. View

4.
Banan R, Christians A, Bartels S, Lehmann U, Hartmann C . Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant. Acta Neuropathol Commun. 2017; 5(1):98. PMC: 5732448. DOI: 10.1186/s40478-017-0500-2. View

5.
Karremann M, Gielen G, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M . Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro Oncol. 2017; 20(1):123-131. PMC: 5761525. DOI: 10.1093/neuonc/nox149. View